Ipca Laboratories upgraded FY27 revenue growth guidance to 14-16 per cent from 12-13 per cent and raised consolidated EBITDA margin guidance to 23 per cent from 22 per cent.
Source: Business Standard
Ipca surges 11% in tepid market, nears 52-week high on healthy Q1 results
Temp User
Listen to News
Click play to hear this story
